US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

1.17

-0.0100-0.85%

Post-market: 1.13-0.0399-3.41%19:52 EDT

Volume:260.14K

Turnover:301.53K

Market Cap:9.85M

PE:-0.96

High:1.19

Open:1.19

Low:1.11

Close:1.18

Loading ...

Overview Company News Filings

Silexion Therapeutics- Pricing of Public Offering of Aggregate 3.7 Mln Ordinary Shares and Warrants at Combined Price of $1.35 per Share and Warrant

THOMSON REUTERS

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

THOMSON REUTERS

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics

Silexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment Data

Silexion Shares Rise Late Following Pretrial Data From Pancreatic Cancer Treatment Showing Efficacy

MT Newswires Live

Silexion Therapeutics Shares up 68% After the Bell; Announces Additional Promising Preclinical Data for Sil-204

THOMSON REUTERS

BRIEF-Silexion Therapeutics Amends Share Purchase Agreement With White Lion Capital

BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics Corp - Amends Share Purchase Agreement With White Lion Capital

THOMSON REUTERS

Silexion Therapeutics Corp - Amendment Introduces Accelerated Purchase Mechanism Until December 31, 2025

THOMSON REUTERS

Silexion Therapeutics Announces Additional Promising Preclinical Data for Sil-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies

THOMSON REUTERS

Silexion Therapeutics Corp - to Initiate Preclinical Studies for Sil-204 in Colorectal Cancer

THOMSON REUTERS

BRIEF-Silexion Therapeutics Files For Offering Of Up To 2.6 Million Ordinary Shares Together With Ordinary Warrants

Silexion Therapeutics Corp Files for Offering of up to 2.6 Mln Ordinary Shares Together With Ordinary Warrants - SEC Filing

THOMSON REUTERS

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLXN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.17,"timestamp":1743192000000,"preClose":1.18,"halted":0,"volume":260144,"hourTrading":{"tag":"盘后","latestPrice":1.1301,"preClose":1.17,"latestTime":"19:52 EDT","volume":4614,"amount":5254.8497,"timestamp":1743205962206},"delay":0,"floatShares":5231700,"shares":8414615,"eps":-1.215216,"marketStatus":"Market Closed","change":-0.01,"latestTime":"03-28 16:00:00 EDT","open":1.19,"high":1.19,"low":1.1127,"amount":301528.644038,"amplitude":0.065508,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.215216,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.18,"preHourTrading":{"tag":"盘前","latestPrice":1.2,"preClose":1.18,"latestTime":"09:22 EDT","volume":33595,"amount":40292.993046,"timestamp":1743168175112},"postHourTrading":{"tag":"盘后","latestPrice":1.1301,"preClose":1.17,"latestTime":"19:52 EDT","volume":4614,"amount":5254.8497,"timestamp":1743205962206},"volumeRatio":1.0749654333989784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"--","roe":"--","lyrEps":0.386244,"volumeRatio":1.0749654333989784,"shares":8414615,"dividePrice":0,"high":1.19,"amplitude":0.065508,"preClose":1.18,"low":1.1127,"week52Low":0.575,"pbRate":"--","week52High":122.0184,"institutionHeld":0,"latestPrice":1.17,"eps":-1.215216,"divideRate":0,"volume":260144,"delay":0,"ttmEps":-1.215216,"open":1.19,"prevYearClose":2.01,"prevWeekClose":1.14,"prevMonthClose":1.07,"prevQuarterClose":2.01,"fiveDayClose":1.14,"twentyDayClose":1.07,"sixtyDayClose":2.27},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503988341","title":"Silexion Therapeutics- Pricing of Public Offering of Aggregate 3.7 Mln Ordinary Shares and Warrants at Combined Price of $1.35 per Share and Warrant","url":"https://stock-news.laohu8.com/highlight/detail?id=2503988341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503988341?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:00","pubTimestamp":1736989200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nTUA8FKGVG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503600794","title":"Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503600794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503600794?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:00","pubTimestamp":1736989200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nTUA8FKGVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2503398880","title":"Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503398880","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503398880?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:00","pubTimestamp":1736989200,"startTime":"0","endTime":"0","summary":"Cayman Islands, January 15, 2025 --Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/16/3010501/0/en/Silexion-Therapeutics-Announces-Pricing-of-5-0-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","SLXN"],"gpt_icon":0},{"id":"2503601701","title":"Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503601701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503601701?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:45","pubTimestamp":1736984700,"startTime":"0","endTime":"0","summary":"Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading.Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading.Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SLXN","US30Y.BOND","US10Y.BOND","BK4139","US5Y.BOND","SER","PMAX","US2Y.BOND","US6M.BOND","BK4078","US3Y.BOND","LENZ","US7Y.BOND","BK4588","GPRO","BK4096","US12M.BOND","BK4112"],"gpt_icon":1},{"id":"2503067006","title":"Silexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2503067006","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503067006?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:05","pubTimestamp":1736982300,"startTime":"0","endTime":"0","summary":"Shares of Silexion Therapeutics surged after the company released what it called promising preclinical data for its treatment of pancreatic cancer.The stock jumped 68%, to $2.61, in after-hours trading Wednesday. Shares ended the regular session 12% lower, at $1.56, putting them down more than 98% in the last year.The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer.Additional preclinical data show that the drug exhibits synergistic activity with 5-fluorouracil and irinotecan--two main components commonly used in pancreatic-cancer treatments--when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer, the company said.Moving forward, Silexion said it will continue developing SIL-204. It plans to initiate toxicology studies with the drug within the upcoming months, as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SLXN","BK4139"],"gpt_icon":0},{"id":"2503603791","title":"Silexion Shares Rise Late Following Pretrial Data From Pancreatic Cancer Treatment Showing Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2503603791","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503603791?lang=en_us&edition=fundamental","pubTime":"2025-01-16 06:23","pubTimestamp":1736979797,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  was 74% higher in Wednesday's after-hours session, after it disclosed preclinical data demonstrated the synergistic efficacy of its SIL-204 candidate to treat certain form of pancreatic cancer.The data show that SIL-204 worked well in combination with the primary components of two chemotherapies, 5-fluorouracil and irinotecan, in human cell lines containing pancreatic cancer with KRAS G12D mutations, the most common form of the disease. SIL-204 also showed synergistic activity with gemcitabine, another chemotherapeutic agent, Silexion said.The company currently is preparing SIL-204 for upcoming clinical trials, with toxicology studies set to begin within a few months and phase 2/3 testing planned for H1 2026, beginning with locally advanced pancreatic cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503770696","title":"Silexion Therapeutics Shares up 68% After the Bell; Announces Additional Promising Preclinical Data for Sil-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2503770696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503770696?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:19","pubTimestamp":1736975985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nL1N3OB18J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503677371","title":"BRIEF-Silexion Therapeutics Amends Share Purchase Agreement With White Lion Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2503677371","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503677371?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:06","pubTimestamp":1736975205,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Amends Share Purchase Agreement With White Lion CapitalJan 15  - Silexion Therapeutics SLXN.O:SILEXION THERAPEUTICS CORP - AMENDS SHARE PURCHASE AGREEMENT WITH WHITE LION CAPITALSILEXION THERAPEUTICS CORP - AMENDMENT INTRODUCES ACCELERATED PURCHASE MECHANISM UNTIL DECEMBER 31, 2025Source text: [ID:n0001178913-25-000130]Further company coverage: SLXN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nFWN3OB0ZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2503672079","title":"BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2503672079","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503672079?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:03","pubTimestamp":1736975016,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer ChemotherapiesJan 15 (Reuters) - Silexion Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUABB5RDK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN"],"gpt_icon":0},{"id":"2503667207","title":"Silexion Therapeutics Corp - Amends Share Purchase Agreement With White Lion Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2503667207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503667207?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:03","pubTimestamp":1736975007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nFWN3OB0ZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503075672","title":"Silexion Therapeutics Corp - Amendment Introduces Accelerated Purchase Mechanism Until December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503075672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503075672?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:03","pubTimestamp":1736975007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nFWN3OB0ZM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2503720166","title":"Silexion Therapeutics Announces Additional Promising Preclinical Data for Sil-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2503720166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503720166?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:01","pubTimestamp":1736974860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUABB5RDK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503720106","title":"Silexion Therapeutics Corp - to Initiate Preclinical Studies for Sil-204 in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503720106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503720106?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:01","pubTimestamp":1736974860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUABB5RDK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503522786","title":"BRIEF-Silexion Therapeutics Files For Offering Of Up To 2.6 Million Ordinary Shares Together With Ordinary Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2503522786","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503522786?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:50","pubTimestamp":1736859029,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Files For Offering Of Up To 2.6 Million Ordinary Shares Together With Ordinary WarrantsJan 14  - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS CORP FILES FOR OFFERING OF UP TO 2.6 MILLION ORDINARY SHARES TOGETHER WITH ORDINARY WARRANTS - SEC FILINGFurther company coverage: SLXN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503952567","title":"Silexion Therapeutics Corp Files for Offering of up to 2.6 Mln Ordinary Shares Together With Ordinary Warrants - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2503952567","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503952567?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:22","pubTimestamp":1736853779,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503640306","title":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2503640306","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503640306?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:50","pubTimestamp":1736772600,"startTime":"0","endTime":"0","summary":"Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers. Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp.  , a clinical-stage biotech developing RNA interference  therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal  Cancers Symposium taking place January 23-25, 2025, in San Francisco, California.Silexion’s abstract will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025. Following the presentation, the poster will be available on Silexion Therapeutics’ website under the “Our Science” section.Title: SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation Presenter: Mitchell Shirvan, Ph.D. Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Abstract Nu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-present-sil-204-125000076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SIL","SLXNW","LENZ","SLXN","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":3,"totalSize":70}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000}}}